O	0	10	Management	Management	NN	B-NP
O	11	13	of	of	IN	B-PP
O	14	19	early	early	JJ	B-NP
O	20	23	and	and	CC	I-NP
O	24	32	advanced	advanced	JJ	I-NP
B-Cancer	33	43	colorectal	colorectal	JJ	I-NP
I-Cancer	44	50	cancer	cancer	NN	I-NP
O	50	51	:	:	:	O
O	52	63	therapeutic	therapeutic	JJ	B-NP
O	64	70	issues	issue	NNS	I-NP
O	70	71	.	.	.	O

O	72	79	PURPOSE	PURPOSE	NN	B-NP
O	79	80	:	:	:	O
O	81	84	The	The	DT	B-NP
O	85	92	staging	staging	NN	I-NP
O	93	95	of	of	IN	B-PP
B-Cancer	96	106	colorectal	colorectal	JJ	B-NP
I-Cancer	107	113	cancer	cancer	NN	I-NP
O	113	114	,	,	,	O
O	115	126	therapeutic	therapeutic	JJ	B-NP
O	127	135	decision	decision	NN	I-NP
O	136	142	making	make	VBG	B-VP
O	143	145	in	in	IN	B-PP
O	146	149	the	the	DT	B-NP
O	150	160	management	management	NN	I-NP
O	161	163	of	of	IN	B-PP
O	164	169	early	early	JJ	B-NP
O	170	173	and	and	CC	I-NP
O	174	182	advanced	advanced	JJ	I-NP
B-Cancer	183	193	colorectal	colorectal	JJ	I-NP
I-Cancer	194	200	cancer	cancer	NN	I-NP
O	200	201	,	,	,	O
O	202	205	and	and	CC	O
O	206	214	dilemmas	dilemma	NNS	B-NP
O	215	220	posed	pose	VBN	B-VP
O	221	223	by	by	IN	B-PP
O	224	228	drug	drug	NN	B-NP
O	228	229	-	-	HYPH	O
O	229	236	related	relate	VBN	B-NP
O	237	245	toxicity	toxicity	NN	I-NP
O	246	249	are	be	VBP	B-VP
O	250	259	discussed	discuss	VBN	I-VP
O	259	260	.	.	.	O

O	261	268	SUMMARY	SUMMARY	NN	B-NP
O	268	269	:	:	:	O
O	270	277	Staging	Staging	NN	B-NP
O	278	280	of	of	IN	B-PP
B-Cancer	281	291	colorectal	colorectal	JJ	B-NP
I-Cancer	292	298	cancer	cancer	NN	I-NP
O	299	305	occurs	occur	VBZ	B-VP
O	306	311	after	after	IN	B-PP
O	312	319	surgery	surgery	NN	B-NP
O	320	323	and	and	CC	O
O	324	326	is	be	VBZ	B-VP
O	327	332	based	base	VBN	I-VP
O	333	335	on	on	IN	B-PP
O	336	339	the	the	DT	B-NP
O	340	346	extent	extent	NN	I-NP
O	347	349	of	of	IN	B-PP
O	350	357	disease	disease	NN	B-NP
O	358	370	invasiveness	invasiveness	NN	I-NP
O	371	374	and	and	CC	I-NP
O	375	388	dissemination	dissemination	NN	I-NP
O	388	389	.	.	.	O

O	390	397	Surgery	Surgery	NNP	B-NP
O	398	400	is	be	VBZ	B-VP
O	401	404	the	the	DT	B-NP
O	405	412	primary	primary	JJ	I-NP
O	413	422	treatment	treatment	NN	I-NP
O	423	426	for	for	IN	B-PP
O	427	432	stage	stage	NN	B-NP
O	433	434	I	I	CD	I-NP
O	435	442	disease	disease	NN	I-NP
O	442	443	.	.	.	O

O	444	452	Adjuvant	Adjuvant	JJ	B-NP
O	453	465	chemotherapy	chemotherapy	NN	I-NP
O	466	468	is	be	VBZ	B-VP
O	469	480	recommended	recommend	VBN	I-VP
O	481	486	after	after	IN	B-PP
O	487	496	resection	resection	NN	B-NP
O	497	499	in	in	IN	B-PP
O	500	508	selected	select	VBN	B-NP
O	509	513	high	high	JJ	I-NP
O	513	514	-	-	HYPH	I-NP
O	514	518	risk	risk	NN	B-NP
O	519	527	patients	patient	NNS	I-NP
O	528	532	with	with	IN	B-PP
O	533	538	stage	stage	NN	B-NP
O	539	541	II	II	CD	I-NP
O	542	549	disease	disease	NN	I-NP
O	550	553	and	and	CC	B-PP
O	554	556	in	in	IN	B-PP
O	557	560	all	all	DT	B-NP
O	561	569	patients	patient	NNS	I-NP
O	570	574	with	with	IN	B-PP
O	575	580	stage	stage	NN	B-NP
O	581	584	III	III	CD	I-NP
O	585	592	disease	disease	NN	I-NP
O	592	593	.	.	.	O

O	594	605	Convenience	Convenience	NN	B-NP
O	606	608	of	of	IN	B-PP
O	609	623	administration	administration	NN	B-NP
O	623	624	,	,	,	O
O	625	637	tolerability	tolerability	NN	B-NP
O	637	638	,	,	,	O
O	639	642	and	and	CC	O
O	643	650	patient	patient	NN	B-NP
O	651	658	factors	factor	NNS	I-NP
O	659	662	not	not	RB	O
O	663	674	necessarily	necessarily	RB	B-ADVP
O	675	678	age	age	NN	B-NP
O	679	682	may	may	MD	B-VP
O	683	685	be	be	VB	I-VP
O	686	700	considerations	consideration	NNS	B-NP
O	701	703	in	in	IN	B-PP
O	704	713	decisions	decision	NNS	B-NP
O	714	719	about	about	IN	B-PP
O	720	728	adjuvant	adjuvant	JJ	B-NP
O	729	736	therapy	therapy	NN	I-NP
O	737	742	after	after	IN	B-PP
O	743	752	resection	resection	NN	B-NP
O	752	753	.	.	.	O

O	754	763	Treatment	Treatment	NN	B-NP
O	764	766	of	of	IN	B-PP
O	767	772	stage	stage	NN	B-NP
O	773	775	IV	IV	CD	I-NP
B-Cancer	776	786	colorectal	colorectal	JJ	I-NP
I-Cancer	787	793	cancer	cancer	NN	I-NP
O	794	796	is	be	VBZ	B-VP
O	797	802	based	base	VBN	I-VP
O	803	805	on	on	IN	B-PP
O	806	809	the	the	DT	B-NP
O	810	814	type	type	NN	I-NP
O	815	817	of	of	IN	B-PP
O	818	823	prior	prior	JJ	B-NP
O	824	831	therapy	therapy	NN	I-NP
O	832	835	and	and	CC	I-NP
O	836	843	patient	patient	NN	I-NP
O	843	844	-	-	HYPH	O
O	844	852	specific	specific	JJ	B-NP
O	853	860	factors	factor	NNS	I-NP
O	860	861	.	.	.	O

O	862	870	Recently	Recently	RB	B-ADVP
O	870	871	,	,	,	O
O	872	883	significant	significant	JJ	B-NP
O	884	896	improvements	improvement	NNS	I-NP
O	897	899	in	in	IN	B-PP
O	900	908	survival	survival	NN	B-NP
O	909	913	have	have	VBP	B-VP
O	914	918	been	be	VBN	I-VP
O	919	927	achieved	achieve	VBN	I-VP
O	928	935	through	through	IN	B-PP
O	936	939	the	the	DT	B-NP
O	940	943	use	use	NN	I-NP
O	944	946	of	of	IN	B-PP
O	947	958	combination	combination	NN	B-NP
O	959	971	chemotherapy	chemotherapy	NN	I-NP
O	972	975	and	and	CC	O
O	976	986	monoclonal	monoclonal	JJ	B-NP
O	987	995	antibody	antibody	NN	I-NP
O	996	1004	regimens	regimen	NNS	I-NP
O	1004	1005	.	.	.	O

O	1006	1017	Bevacizumab	Bevacizumab	NN	B-NP
O	1018	1020	in	in	IN	B-PP
O	1021	1032	combination	combination	NN	B-NP
O	1033	1037	with	with	IN	B-PP
O	1038	1050	chemotherapy	chemotherapy	NN	B-NP
O	1051	1053	is	be	VBZ	B-VP
O	1054	1059	first	first	JJ	B-ADJP
O	1059	1060	-	-	HYPH	B-NP
O	1060	1064	line	line	NN	I-NP
O	1065	1072	therapy	therapy	NN	I-NP
O	1073	1076	for	for	IN	B-PP
O	1077	1082	stage	stage	NN	B-NP
O	1083	1085	IV	IV	CD	I-NP
O	1086	1093	disease	disease	NN	I-NP
O	1093	1094	.	.	.	O

O	1095	1098	Age	Age	NN	B-NP
O	1099	1104	alone	alone	RB	B-ADVP
O	1105	1111	should	should	MD	B-VP
O	1112	1115	not	not	RB	I-VP
O	1116	1124	preclude	preclude	VB	I-VP
O	1125	1128	the	the	DT	B-NP
O	1129	1132	use	use	NN	I-NP
O	1133	1135	of	of	IN	B-PP
O	1136	1148	chemotherapy	chemotherapy	NN	B-NP
O	1149	1151	in	in	IN	B-PP
O	1152	1157	stage	stage	NN	B-NP
O	1158	1160	IV	IV	CD	I-NP
B-Cancer	1161	1171	colorectal	colorectal	JJ	I-NP
I-Cancer	1172	1178	cancer	cancer	NN	I-NP
O	1178	1179	,	,	,	O
O	1180	1188	although	although	IN	B-SBAR
O	1189	1192	the	the	DT	B-NP
O	1193	1200	ability	ability	NN	I-NP
O	1201	1203	to	to	TO	B-VP
O	1204	1212	tolerate	tolerate	VB	I-VP
O	1213	1217	drug	drug	NN	B-NP
O	1217	1218	-	-	HYPH	O
O	1218	1225	related	relate	VBN	B-NP
O	1226	1234	toxicity	toxicity	NN	I-NP
O	1235	1238	may	may	MD	B-VP
O	1239	1241	be	be	VB	I-VP
O	1242	1243	a	a	DT	B-NP
O	1244	1257	consideration	consideration	NN	I-NP
O	1257	1258	.	.	.	O

O	1259	1262	The	The	DT	B-NP
O	1263	1270	optimal	optimal	JJ	I-NP
O	1271	1279	duration	duration	NN	I-NP
O	1280	1282	of	of	IN	B-PP
O	1283	1295	chemotherapy	chemotherapy	NN	B-NP
O	1296	1298	in	in	IN	B-PP
O	1299	1307	patients	patient	NNS	B-NP
O	1308	1312	with	with	IN	B-PP
O	1313	1318	early	early	JJ	B-NP
O	1319	1322	and	and	CC	I-NP
B-Cancer	1323	1333	metastatic	metastatic	JJ	I-NP
I-Cancer	1334	1344	colorectal	colorectal	JJ	I-NP
I-Cancer	1345	1351	cancer	cancer	NN	I-NP
O	1352	1354	is	be	VBZ	B-VP
O	1355	1362	unclear	unclear	JJ	B-ADJP
O	1362	1363	.	.	.	O

O	1364	1374	CONCLUSION	CONCLUSION	NN	B-NP
O	1374	1375	:	:	:	O
O	1376	1379	The	The	DT	B-NP
O	1380	1387	optimal	optimal	JJ	I-NP
O	1388	1396	approach	approach	NN	I-NP
O	1397	1399	to	to	TO	B-PP
O	1400	1403	the	the	DT	B-NP
O	1404	1413	treatment	treatment	NN	I-NP
O	1414	1416	of	of	IN	B-PP
B-Cancer	1417	1427	colorectal	colorectal	JJ	B-NP
I-Cancer	1428	1434	cancer	cancer	NN	I-NP
O	1435	1442	depends	depend	VBZ	B-VP
O	1443	1445	on	on	IN	B-PP
O	1446	1453	several	several	JJ	B-NP
O	1454	1468	considerations	consideration	NNS	I-NP
O	1468	1469	,	,	,	O
O	1470	1479	including	include	VBG	B-PP
O	1480	1487	patient	patient	NN	B-NP
O	1487	1488	-	-	HYPH	O
O	1488	1496	specific	specific	JJ	B-NP
O	1497	1504	factors	factor	NNS	I-NP
O	1504	1505	.	.	.	O

